



PRESS RELEASE

June 19, 2023

Ziccum sponsors the Global mRNA-Based Therapeutics Summit, Boston MA, July 26-28

Ziccum AB (publ) is sponsoring one of the most well-attended international events in the field of mRNA-based therapeutics in Boston MA, July 26-28. Ziccum CEO Ann Gidner will present the company's unique drying technology for biopharmaceuticals. Furthermore, the company will exhibit a Poster on its current in-house mRNA project, successfully drying active mRNA materials into a thermostable bioactive dry powder.

mRNA-based therapeutics and vaccines is one of the fastest-growing fields within biopharmaceuticals, with over 800 mRNA drug projects currently in development. A central event in the scientific and business calendar for mRNA professionals is the Global mRNA-Based Therapeutics Summit. The 3rd summit will take place July 26-28 in Boston MA.

Ziccum CEO Ann Gidner will present on Day 1 of the event, Thursday July 27. Her Presentation is titled *A Novel Unit Operation Successfully Drying mRNA/LNP by Mass Transfer*. It will cover the technology principle allowing for ambient drying, its valuable thermostability effects and the implementation for industrial use.

Ziccum will also take part in the Poster Exhibition at the event, outlining aspects from the latest stage of its milestone in-house mRNA project. On March 20, 2023, the company announced that it had successfully nebulized and dried active mRNA materials, plus demonstrated a commercially viable level of mRNA activity.

CEO Ann Gidner: "The Summit is a landmark event for the international business and scientific mRNA community – and we believe that our unique capabilities within mRNA make our technology a key topic here. We look forward to sponsoring, networking and presenting at the event."

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is Erik Penser Bank AB
Follow us on <https://eucaps.com/ziccum>

About Ziccum

Ziccum is developing LaminarPace™, a unique ambient drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

[Ziccum sponsors the Global mRNA-Based Therapeutics Summit, Boston MA, July 26-28](#)